Research Team

Principal Investigator

Norman Lacayo, MD

Associate Professor

Norman Lacayo, MD received his BA in Biochemistry from UC Berkeley, and his MD from UC San Francisco School of Medicine (UCSF). He completed his residency in Pediatrics at UCSF and fellowship in Pediatric Hematology/Oncology/Stem Cell Transplantation at Stanford University. Dr. Lacayo is currently an Associate Professor of Pediatrics, a member of the Stanford Cancer Institute, and Lucile Packard Children's Hospital Stanford (LPCHS). At LPCHS he is the Co-Director of the Leukemia Program and Interim Oncology Section Leader. Dr. Lacayo's research focuses on the discovery and evaluation of new biomarkers in childhood acute leukemia. He actively collaborates with the Children's Oncology Group, led the ADVL0114 study using Decitabine for relapse and refractory leukemia, and is currently a member of the COG Myeloid Committee. Also participated in the St. Jude AML Consortium Trials AML02, AML08 and AML16. Dr. Lacayo became the first institutional PI for the Pediatric Oncology Experimental Therapies Investigational Consortium (POETIC) group in October 2015.

Co-Principal Investigator

Allie Pribnow, MD, MPH

Dr. Pribnow, MD, MPH received her BA in Spanish Foreign Language & Literature from Whitman College, her MPH from Oregon State University, and her MD from Oregon Health & Sciences University (OHSU). She completed her residency training in Pediatrics at Stanford University and her fellowship in Pediatric Hematology/Oncology at St. Jude Children’s Research Hospital. Dr. Pribnow is currently a Clinical Assistant Professor at Stanford University and an attending physician at Lucile Packard Children’s Hospital Stanford (LPCHS). She is the Co-Chair of the Local Improvement Team for the Bass Center for Childhood Cancer & Blood Diseases at LPCHS and of the Chemotherapy Safety Committee. Dr. Pribnow is a member of the Children’s Oncology Group (COG) and currently serving as the COG Adolescent and Young Adult (AYA) Responsible Investigator for the LPCHS site. She has a clinical concentration in solid tumors with a focus on management of bone sarcomas. Her academic interests include treatment of recurrent/refractory OS and EWS, AYA oncology and global oncology.

POETIC DCC Clinical Research

Ativ Zomet, PhD

Program Manager

Ativ Zomet, PhD received her PhD in Neuroscience from Tel Aviv University.  Dr. Zomet is an experienced researcher leading pioneering interventional and devices clinical research both in academia and industry.  She manages complex interventional investigator-initiated, sponsor-initiated, and NCTN studies (phase I, II & III) cancer clinical trials. She also managed clinical research for neuro-plasticity devices. Working as part of an R&D team, she has developed rehabilitative targeted brain training programs to promote greater cognitive plasticity for individuals suffering from brain injury, visually impairments, and psychiatric disorders.

Research Pharmacist

Namrata Patel, PharmD

Namrata joined the pharmacy team at Lucile Packard Children's Hospital at Stanford in 2010 and has since become the Investigational Drug Pharmacist for the Divisions of Hematology/Oncology and Stem Cell Transplantation and Regenerative Medicine. Dr. Patel is a graduate of the University of North Carolina at Chape Hill. She completed a residency at UCSF in 2010. Namrata obtained her Pharmacy Board Certification in Oncology (BCOP) in 2017. She works with all early phase trials at LPCHS to include New Approaches to Neuroblastoma Therapy (NANT) Consortium, the Pediatric Brain Tumor Consortium (PBTC) and participates in St. Jude Children's Research Hospital studies and numerous industry sponsored studies. Dr. Patel is the COG Study Pharmacist (Protocol ACNS1721) and is a pharmacy consultant for the American Association of Blood Banks (AABB) Medication Deferral List Task Force.